Date:_	2021/9/28
Your N	Guoxian Long
Manus	Title:_The clinical prognostic value of PD-L1 after concurrent chemoradiotherapy in Chinese nasopharyngeal
carcino	patients
Manus	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	_ ∠ _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	4 11	
6	Payment for expert testimony	<u>✓</u> None	
	testimony		
7	Support for attending	✓ None	
	meetings and/or travel		
8	Patents planned, issued or	<u>✓</u> _None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <u>v</u> _None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	✓ None	
12	Receipt of equipment,	_ _None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ ∠ _None	
	financial interests		

				CI. .	· · ·	- · -			
DIASCA	summarize	tho s	$\Delta N \Delta M$	CONTLICT	At INTARA	ct in t	tha tal	lowing	hov
ricase	3ullillialize	uic a		COILLICE	OI IIILEIE	St III I	LIIE IUI	IUVVIIIS	$\mathbf{D}\mathbf{D}\mathbf{A}$

The author has no conflicts of interest to declare.	

Date:	2021/9/28	
Your Na	me:Xiaoyu Li	
Manusc	ript Title:_The clinical prognost	ic value of PD-L1 after concurrent chemoradiotherapy in Chinese nasopharyngeal
carcinon	na patients	
Manusc	ript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	_ ✓ _None	

5	Payment or honoraria for	_ ∠ _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	4 11	
6	Payment for expert testimony	<u>✓</u> None	
	testimony		
7	Support for attending	✓ None	
	meetings and/or travel		
8	Patents planned, issued or	<u>✓</u> _None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <u>v</u> _None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	✓ None	
12	Receipt of equipment,	_ _None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ ∠ _None	
	financial interests		

				CI. .	· · ·	- · -			
DIASCA	summarize	tho s	$\Delta N \Delta M$	CONTLICT	At INTARA	ct in t	tha tal	lowing	hov
ricase	3ullillialize	uic a		COILLICE	OI IIILEIE	St III I	LIIE IUI	IUVVIIIS	$\mathbf{D}\mathbf{D}\mathbf{A}$

The author has no conflicts of interest to declare.	

Date:_	2021/9/28	
Your N	ame:Lin Yang	
Manus	cript Title:_The clinical prognosti	ic value of PD-L1 after concurrent chemoradiotherapy in Chinese nasopharyngeal
carcino	ma patients	
Manus	cript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	_ ∠ _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	4 11	
6	Payment for expert testimony	<u>✓</u> None	
	testimony		
7	Support for attending	✓ None	
	meetings and/or travel		
8	Patents planned, issued or	<u>✓</u> _None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <u>v</u> _None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	✓ None	
12	Receipt of equipment,	_ _None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ ∠ _None	
	financial interests		

				CI. .	· · ·	- · -			
DIASCA	summarize	tho s	$\Delta N \Delta M$	CONTLICT	At INTARA	ct in t	tha tal	lowing	hov
ricase	3ullillialize	uic a		COILLICE	OI IIILEIE	St III I	LIIE IUI	IUVVIIIS	$\mathbf{D}\mathbf{D}\mathbf{A}$

The author has no conflicts of interest to declare.	

Date:	2021/9/28	
Your Na	me:Jing Zhao	
Manusc	ript Title:_The clinical prognos	tic value of PD-L1 after concurrent chemoradiotherapy in Chinese nasopharyngea
carcinor	ma patients	
Manusc	ript number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	_ ∠ _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	4 11	
6	Payment for expert testimony	<u>✓</u> None	
	testimony		
7	Support for attending	✓ None	
	meetings and/or travel		
8	Patents planned, issued or	<u>✓</u> _None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <u>v</u> _None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	✓ None	
12	Receipt of equipment,	_ _None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ ∠ _None	
	financial interests		

				CI. .	· · ·	- · -			
DIASCA	summarize	tho s	$\Delta N \Delta M$	CONTLICT	At INTARA	ct in t	tha tal	lowing	hov
ricase	3ullillialize	uic a		COILLICE	OI IIILEIE	St III I	LIIE IUI	IUVVIIIS	$\mathbf{D}\mathbf{D}\mathbf{A}$

The author has no conflicts of interest to declare.	

Date:	2021/9/28	
Your Name:_	Xiang Lu	
Manuscript T	itle:_The clinical progno	ostic value of PD-L1 after concurrent chemoradiotherapy in Chinese nasopharyngea
carcinoma pa	tients	
Manuscript n	umber (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	_ ∠ _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	4 11	
6	Payment for expert testimony	<u>✓</u> None	
	testimony		
7	Support for attending	✓ None	
	meetings and/or travel		
8	Patents planned, issued or	<u>✓</u> _None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <u>v</u> _None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	✓ None	
12	Receipt of equipment,	_ _None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ ∠ _None	
	financial interests		

				CI. .	· · ·	- · -			
DIASCA	summarize	tho s	$\Delta N \Delta M$	CONTLICT	At INTARA	ct in t	tha tal	lowing	hov
ricase	3ullillialize	uic a		COILLICE	OI IIILEIE	St III I	LIIE IUI	IUVVIIIS	$\mathbf{D}\mathbf{D}\mathbf{A}$

The author has no conflicts of interest to declare.	

Date:	2021/9/28	
Your Name:	Heng Wang	
Manuscript	Title:_The clinical prognos	tic value of PD-L1 after concurrent chemoradiotherapy in Chinese nasopharyngea
carcinoma p	atients	
Manuscript	number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	_ ∠ _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	4 11	
6	Payment for expert testimony	<u>✓</u> None	
	testimony		
7	Support for attending	✓ None	
	meetings and/or travel		
8	Patents planned, issued or	<u>✓</u> _None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <u>v</u> _None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	✓ None	
12	Receipt of equipment,	_ _None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ ∠ _None	
	financial interests		

				CI. .	· · ·	- · -			
DIASCA	summarize	tho s	$\Delta N \Delta M$	CONTLICT	At INTARA	ct in t	tha tal	lowing	hov
ricase	3ullillial IZC	uic a		COILLICE	OI IIILEIE	St III I	LIIE IUI	IUVVIIIS	$\mathbf{D}\mathbf{D}\mathbf{A}$

The author has no conflicts of interest to declare.	

Date:	_2021/9/28
Your Name:	Jia Song
Manuscript Titl	e:_The clinical prognostic value of PD-L1 after concurrent chemoradiotherapy in Chinese nasopharynge
carcinoma patie	ents
Manuscript nui	mber (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for	_ ∠ _None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	4 11	
6	Payment for expert testimony	<u>✓</u> None	
	testimony		
7	Support for attending	✓ None	
	meetings and/or travel		
8	Patents planned, issued or	<u>✓</u> _None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <u>v</u> _None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	✓ None	
12	Receipt of equipment,	_ _None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ ∠ _None	
	financial interests		

				CI. .	· · ·	- · -			
DIASCA	summarize	tho s	$\Delta N \Delta M$	CONTLICT	At INTARA	ct in t	tha tal	lowing	hov
ricase	3ullillial IZC	uic a		COILLICE	OI IIILEIE	St III I	LIIE IUI	IUVVIIIS	$\mathbf{D}\mathbf{D}\mathbf{A}$

The author has no conflicts of interest to declare.	

Date:	2021/9/28	
Your Name:	Qi Mei	
Manuscript	Title:_The clinical progr	nostic value of PD-L1 after concurrent chemoradiotherapy in Chinese nasopharyngea
carcinoma p	atients	
Manuscript	number (if known):	

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	_ ∠ _None	
	speakers bureaus,		
	manuscript writing or		
_	educational events	4 11	
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	✓ None	
	meetings and/or travel		
8	Patents planned, issued or	<u>✓</u> _None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <u>v</u> _None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	✓ None	
12	Receipt of equipment,	_ _None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ ⊻ _None	
	financial interests		

				CI. .					
DIASCA	summarize	tho s	Shove	CONTLICT	At INTARA	ct in t	'ha tal	LOWING	hov
ricase	3ullillial IZC	uic a		COILLICE	OI IIILEIE	JL III L	.iie ioi	IUWIIIE	$\mathbf{D}\mathbf{D}\mathbf{A}$

The author has no conflicts of interest to declare.	

Date:_	2021/9/28
Your N	Guangyuan Hu
Manus	Title:_The clinical prognostic value of PD-L1 after concurrent chemoradiotherapy in Chinese nasopharynge
carcino	atients
Manus	number (if known):

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

5	Payment or honoraria for lectures, presentations,	_ ∠ _None	
	speakers bureaus,		
	manuscript writing or		
_	educational events	4 11	
6	Payment for expert testimony	None	
	testimony		
7	Support for attending	✓ None	
	meetings and/or travel		
8	Patents planned, issued or	<u>✓</u> _None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ <u>v</u> _None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	✓ None	
12	Receipt of equipment,	_ _None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	_ ⊻ _None	
	financial interests		

				CI. .					
DIASCA	summarize	tho s	Shove	CONTLICT	At INTARA	ct in t	'ha tal	LOWING	hov
ricase	3ullillial IZC	uic a		COILLICE	OI IIILEIE	JL III L	.iie ioi	IUWIIIE	$\mathbf{D}\mathbf{D}\mathbf{A}$

The author has no conflicts of interest to declare.	